RNA-based stool test maker for colorectal cancer screening
Geneoscopy commercializes an FDA-approved, RNA-based stool test for colorectal cancer screening, built on its own seRNA biomarker platform. Hiring is accelerating and skews heavily toward senior sales roles, pointing to a field-driven commercial push, while a Salesforce stack with Apex and Visualforce plus NetSuite suggests custom CRM-to-order workflows. A Kubernetes/EKS, Helm, Flux and GitLab CI/CD setup indicates in-house software infrastructure alongside LIMS-based lab operations.
Geneoscopy is a St. Louis, MO life sciences company founded in 2015 that develops noninvasive diagnostics for gastrointestinal health. Its ColoSense test screens average-risk adults over 45 for colorectal cancer and advanced adenomas using RNA biomarkers extracted from stool. The company also works with academic and biopharma partners on GI tests that could guide therapy choices and track patient response, including in areas such as IBD. Geneoscopy is privately held, employs 51–200 people and hires within the United States.
Geneoscopy uses Salesforce (Apex, Visualforce), NetSuite, Sage Intacct, AWS with EKS, Kubernetes, Helm, Flux and Docker, GitLab CI/CD, LIMS, ddPCR, Tableau, Jira and Smartsheet.
Yes. Hiring is accelerating and concentrated in senior sales roles across the United States, with smaller openings in operations, engineering and quality.
Geneoscopy is headquartered in St. Louis, Missouri, and has 51–200 employees. It was founded in 2015.
Other companies in the same industry, closest in size
Geneoscopy's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.